Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC476521 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.9924 | High Similarity | NPC476522 |
0.9924 | High Similarity | NPC476013 |
0.9924 | High Similarity | NPC474986 |
0.9774 | High Similarity | NPC476520 |
0.9699 | High Similarity | NPC476433 |
0.9699 | High Similarity | NPC476528 |
0.9697 | High Similarity | NPC470266 |
0.9621 | High Similarity | NPC296437 |
0.9416 | High Similarity | NPC476408 |
0.8973 | High Similarity | NPC472832 |
0.8973 | High Similarity | NPC18308 |
0.8936 | High Similarity | NPC244700 |
0.8828 | High Similarity | NPC472834 |
0.8767 | High Similarity | NPC472833 |
0.8392 | Intermediate Similarity | NPC217656 |
0.825 | Intermediate Similarity | NPC473585 |
0.8082 | Intermediate Similarity | NPC89139 |
0.7939 | Intermediate Similarity | NPC265111 |
0.7045 | Intermediate Similarity | NPC174114 |
0.7045 | Intermediate Similarity | NPC87981 |
0.6941 | Remote Similarity | NPC317054 |
0.6883 | Remote Similarity | NPC167285 |
0.6774 | Remote Similarity | NPC76544 |
0.6774 | Remote Similarity | NPC226184 |
0.6755 | Remote Similarity | NPC57279 |
0.6705 | Remote Similarity | NPC164845 |
0.6522 | Remote Similarity | NPC476564 |
0.6522 | Remote Similarity | NPC18335 |
0.6405 | Remote Similarity | NPC104011 |
0.637 | Remote Similarity | NPC68938 |
0.6329 | Remote Similarity | NPC33996 |
0.6294 | Remote Similarity | NPC4837 |
0.6294 | Remote Similarity | NPC312187 |
0.6289 | Remote Similarity | NPC129756 |
0.6272 | Remote Similarity | NPC239737 |
0.6201 | Remote Similarity | NPC477119 |
0.6196 | Remote Similarity | NPC313514 |
0.6176 | Remote Similarity | NPC476219 |
0.6149 | Remote Similarity | NPC317821 |
0.6108 | Remote Similarity | NPC150853 |
0.609 | Remote Similarity | NPC246193 |
0.6089 | Remote Similarity | NPC313897 |
0.6082 | Remote Similarity | NPC476297 |
0.6082 | Remote Similarity | NPC93365 |
0.6062 | Remote Similarity | NPC469308 |
0.6059 | Remote Similarity | NPC469975 |
0.6049 | Remote Similarity | NPC161659 |
0.6049 | Remote Similarity | NPC209525 |
0.604 | Remote Similarity | NPC189314 |
0.6 | Remote Similarity | NPC470203 |
0.6 | Remote Similarity | NPC477118 |
0.5977 | Remote Similarity | NPC300238 |
0.5976 | Remote Similarity | NPC314152 |
0.5976 | Remote Similarity | NPC229974 |
0.5968 | Remote Similarity | NPC477120 |
0.5964 | Remote Similarity | NPC189068 |
0.5943 | Remote Similarity | NPC470204 |
0.5928 | Remote Similarity | NPC309832 |
0.5928 | Remote Similarity | NPC219313 |
0.5904 | Remote Similarity | NPC107374 |
0.5904 | Remote Similarity | NPC156461 |
0.5904 | Remote Similarity | NPC21448 |
0.5896 | Remote Similarity | NPC120070 |
0.5882 | Remote Similarity | NPC114209 |
0.5871 | Remote Similarity | NPC248007 |
0.5868 | Remote Similarity | NPC164665 |
0.5858 | Remote Similarity | NPC136349 |
0.5833 | Remote Similarity | NPC269827 |
0.5799 | Remote Similarity | NPC121222 |
0.5792 | Remote Similarity | NPC189261 |
0.5789 | Remote Similarity | NPC161224 |
0.5783 | Remote Similarity | NPC8590 |
0.5771 | Remote Similarity | NPC195140 |
0.5767 | Remote Similarity | NPC158055 |
0.5763 | Remote Similarity | NPC122141 |
0.5756 | Remote Similarity | NPC328479 |
0.5749 | Remote Similarity | NPC250178 |
0.573 | Remote Similarity | NPC225018 |
0.5724 | Remote Similarity | NPC476099 |
0.5723 | Remote Similarity | NPC212551 |
0.5723 | Remote Similarity | NPC302778 |
0.5698 | Remote Similarity | NPC85689 |
0.5698 | Remote Similarity | NPC211025 |
0.5698 | Remote Similarity | NPC185991 |
0.569 | Remote Similarity | NPC174802 |
0.5677 | Remote Similarity | NPC139776 |
0.5665 | Remote Similarity | NPC472816 |
0.5665 | Remote Similarity | NPC321814 |
0.5657 | Remote Similarity | NPC224076 |
0.5657 | Remote Similarity | NPC276373 |
0.5632 | Remote Similarity | NPC164952 |
0.5632 | Remote Similarity | NPC40070 |
0.5632 | Remote Similarity | NPC130586 |
0.5628 | Remote Similarity | NPC5802 |
0.5628 | Remote Similarity | NPC160666 |
0.5625 | Remote Similarity | NPC226245 |
0.5625 | Remote Similarity | NPC14330 |
0.5611 | Remote Similarity | NPC317105 |
0.561 | Remote Similarity | NPC471603 |
0.5608 | Remote Similarity | NPC24589 |
0.5607 | Remote Similarity | NPC201380 |
0.5607 | Remote Similarity | NPC179787 |
0.5607 | Remote Similarity | NPC470111 |
0.5604 | Remote Similarity | NPC290959 |
0.56 | Remote Similarity | NPC157821 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC476521 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.7279 | Intermediate Similarity | NPD1058 | Discontinued |
0.7091 | Intermediate Similarity | NPD1313 | Approved |
0.6786 | Remote Similarity | NPD1333 | Phase 3 |
0.6725 | Remote Similarity | NPD1567 | Clinical (unspecified phase) |
0.6724 | Remote Similarity | NPD2930 | Clinical (unspecified phase) |
0.6707 | Remote Similarity | NPD6074 | Clinical (unspecified phase) |
0.6686 | Remote Similarity | NPD5962 | Phase 2 |
0.6685 | Remote Similarity | NPD3378 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD1015 | Phase 2 |
0.6667 | Remote Similarity | NPD2875 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD1016 | Phase 2 |
0.6629 | Remote Similarity | NPD3341 | Clinical (unspecified phase) |
0.6607 | Remote Similarity | NPD2593 | Clinical (unspecified phase) |
0.6604 | Remote Similarity | NPD7158 | Phase 1 |
0.66 | Remote Similarity | NPD870 | Clinical (unspecified phase) |
0.6588 | Remote Similarity | NPD8120 | Approved |
0.6588 | Remote Similarity | NPD8121 | Phase 3 |
0.6576 | Remote Similarity | NPD7023 | Clinical (unspecified phase) |
0.6557 | Remote Similarity | NPD3485 | Clinical (unspecified phase) |
0.655 | Remote Similarity | NPD1215 | Discontinued |
0.6548 | Remote Similarity | NPD516 | Clinical (unspecified phase) |
0.6543 | Remote Similarity | NPD6129 | Phase 2 |
0.6538 | Remote Similarity | NPD3419 | Clinical (unspecified phase) |
0.6527 | Remote Similarity | NPD2927 | Phase 3 |
0.6524 | Remote Similarity | NPD6816 | Phase 3 |
0.6522 | Remote Similarity | NPD8836 | Approved |
0.6512 | Remote Similarity | NPD2333 | Discontinued |
0.6491 | Remote Similarity | NPD5269 | Clinical (unspecified phase) |
0.648 | Remote Similarity | NPD2456 | Phase 2 |
0.648 | Remote Similarity | NPD2457 | Phase 2 |
0.6477 | Remote Similarity | NPD7111 | Discontinued |
0.6474 | Remote Similarity | NPD2965 | Clinical (unspecified phase) |
0.6467 | Remote Similarity | NPD9408 | Phase 3 |
0.6467 | Remote Similarity | NPD5969 | Clinical (unspecified phase) |
0.6461 | Remote Similarity | NPD4649 | Clinical (unspecified phase) |
0.6457 | Remote Similarity | NPD3799 | Suspended |
0.6447 | Remote Similarity | NPD9633 | Phase 3 |
0.6438 | Remote Similarity | NPD4240 | Approved |
0.6433 | Remote Similarity | NPD799 | Phase 1 |
0.642 | Remote Similarity | NPD5843 | Discontinued |
0.6413 | Remote Similarity | NPD6619 | Phase 3 |
0.6413 | Remote Similarity | NPD3430 | Approved |
0.6413 | Remote Similarity | NPD3431 | Approved |
0.641 | Remote Similarity | NPD4352 | Phase 1 |
0.6405 | Remote Similarity | NPD248 | Discontinued |
0.6402 | Remote Similarity | NPD4568 | Phase 2 |
0.6359 | Remote Similarity | NPD6761 | Discontinued |
0.6358 | Remote Similarity | NPD6794 | Approved |
0.6354 | Remote Similarity | NPD7323 | Phase 2 |
0.6348 | Remote Similarity | NPD5730 | Phase 2 |
0.6348 | Remote Similarity | NPD40 | Phase 2 |
0.6347 | Remote Similarity | NPD2524 | Discontinued |
0.6324 | Remote Similarity | NPD7722 | Suspended |
0.6319 | Remote Similarity | NPD2793 | Discontinued |
0.6319 | Remote Similarity | NPD4902 | Discontinued |
0.6319 | Remote Similarity | NPD2591 | Phase 2 |
0.6313 | Remote Similarity | NPD5508 | Phase 1 |
0.6298 | Remote Similarity | NPD5463 | Clinical (unspecified phase) |
0.6292 | Remote Similarity | NPD3041 | Approved |
0.6278 | Remote Similarity | NPD2526 | Phase 2 |
0.6278 | Remote Similarity | NPD1637 | Clinical (unspecified phase) |
0.6278 | Remote Similarity | NPD2523 | Phase 2 |
0.6277 | Remote Similarity | NPD5462 | Discontinued |
0.6271 | Remote Similarity | NPD7006 | Approved |
0.6264 | Remote Similarity | NPD2647 | Phase 3 |
0.6264 | Remote Similarity | NPD2478 | Clinical (unspecified phase) |
0.6257 | Remote Similarity | NPD1892 | Phase 2 |
0.6257 | Remote Similarity | NPD3409 | Phase 1 |
0.6257 | Remote Similarity | NPD1893 | Phase 2 |
0.625 | Remote Similarity | NPD1257 | Approved |
0.625 | Remote Similarity | NPD3696 | Approved |
0.625 | Remote Similarity | NPD6827 | Clinical (unspecified phase) |
0.625 | Remote Similarity | NPD6828 | Phase 2 |
0.625 | Remote Similarity | NPD3695 | Approved |
0.6243 | Remote Similarity | NPD6469 | Phase 3 |
0.6243 | Remote Similarity | NPD6468 | Clinical (unspecified phase) |
0.6242 | Remote Similarity | NPD4763 | Clinical (unspecified phase) |
0.6237 | Remote Similarity | NPD2452 | Phase 2 |
0.6237 | Remote Similarity | NPD2451 | Phase 2 |
0.6237 | Remote Similarity | NPD4615 | Phase 2 |
0.6237 | Remote Similarity | NPD2839 | Phase 2 |
0.6237 | Remote Similarity | NPD2453 | Phase 2 |
0.6237 | Remote Similarity | NPD2450 | Phase 2 |
0.6236 | Remote Similarity | NPD2406 | Clinical (unspecified phase) |
0.623 | Remote Similarity | NPD6721 | Phase 1 |
0.6216 | Remote Similarity | NPD5145 | Clinical (unspecified phase) |
0.6215 | Remote Similarity | NPD5324 | Clinical (unspecified phase) |
0.6205 | Remote Similarity | NPD4612 | Discontinued |
0.6199 | Remote Similarity | NPD5300 | Clinical (unspecified phase) |
0.6196 | Remote Similarity | NPD7138 | Phase 2 |
0.6196 | Remote Similarity | NPD171 | Discontinued |
0.6188 | Remote Similarity | NPD5806 | Clinical (unspecified phase) |
0.6186 | Remote Similarity | NPD2876 | Phase 3 |
0.6186 | Remote Similarity | NPD2877 | Clinical (unspecified phase) |
0.618 | Remote Similarity | NPD7297 | Phase 2 |
0.6176 | Remote Similarity | NPD6849 | Phase 2 |
0.6176 | Remote Similarity | NPD6850 | Phase 2 |
0.6154 | Remote Similarity | NPD7445 | Phase 1 |
0.615 | Remote Similarity | NPD6577 | Clinical (unspecified phase) |
0.6146 | Remote Similarity | NPD6151 | Phase 2 |
0.6142 | Remote Similarity | NPD6192 | Phase 3 |
0.6141 | Remote Similarity | NPD5682 | Phase 3 |
0.6141 | Remote Similarity | NPD5684 | Clinical (unspecified phase) |
0.6141 | Remote Similarity | NPD5683 | Clinical (unspecified phase) |
0.6141 | Remote Similarity | NPD5642 | Approved |
0.6138 | Remote Similarity | NPD3362 | Clinical (unspecified phase) |
0.6135 | Remote Similarity | NPD174 | Discontinued |
0.6134 | Remote Similarity | NPD5012 | Phase 2 |
0.6129 | Remote Similarity | NPD2818 | Discontinued |
0.6122 | Remote Similarity | NPD6521 | Phase 3 |
0.6122 | Remote Similarity | NPD2824 | Phase 2 |
0.6122 | Remote Similarity | NPD6520 | Phase 3 |
0.6114 | Remote Similarity | NPD509 | Phase 3 |
0.6114 | Remote Similarity | NPD3889 | Approved |
0.6095 | Remote Similarity | NPD1027 | Approved |
0.6095 | Remote Similarity | NPD3107 | Discontinued |
0.6095 | Remote Similarity | NPD1030 | Approved |
0.6095 | Remote Similarity | NPD1029 | Clinical (unspecified phase) |
0.6091 | Remote Similarity | NPD3860 | Discontinued |
0.6089 | Remote Similarity | NPD6470 | Phase 3 |
0.6084 | Remote Similarity | NPD4182 | Phase 3 |
0.6084 | Remote Similarity | NPD4183 | Phase 3 |
0.6082 | Remote Similarity | NPD2646 | Discontinued |
0.6082 | Remote Similarity | NPD2364 | Suspended |
0.6082 | Remote Similarity | NPD546 | Clinical (unspecified phase) |
0.6075 | Remote Similarity | NPD7504 | Discontinued |
0.6066 | Remote Similarity | NPD4441 | Phase 2 |
0.6062 | Remote Similarity | NPD4142 | Discontinued |
0.6062 | Remote Similarity | NPD4318 | Clinical (unspecified phase) |
0.6059 | Remote Similarity | NPD3612 | Phase 2 |
0.6054 | Remote Similarity | NPD2963 | Phase 1 |
0.6053 | Remote Similarity | NPD2960 | Clinical (unspecified phase) |
0.6053 | Remote Similarity | NPD306 | Approved |
0.6049 | Remote Similarity | NPD193 | Suspended |
0.6048 | Remote Similarity | NPD1690 | Clinical (unspecified phase) |
0.6044 | Remote Similarity | NPD702 | Clinical (unspecified phase) |
0.6044 | Remote Similarity | NPD1873 | Clinical (unspecified phase) |
0.6044 | Remote Similarity | NPD4716 | Approved |
0.604 | Remote Similarity | NPD8833 | Approved |
0.604 | Remote Similarity | NPD8831 | Approved |
0.6039 | Remote Similarity | NPD6352 | Phase 2 |
0.6034 | Remote Similarity | NPD5996 | Clinical (unspecified phase) |
0.603 | Remote Similarity | NPD4863 | Approved |
0.6023 | Remote Similarity | NPD1303 | Phase 1 |
0.6022 | Remote Similarity | NPD2731 | Phase 2 |
0.6022 | Remote Similarity | NPD1272 | Clinical (unspecified phase) |
0.6022 | Remote Similarity | NPD6418 | Phase 1 |
0.6021 | Remote Similarity | NPD2880 | Discontinued |
0.602 | Remote Similarity | NPD4023 | Clinical (unspecified phase) |
0.602 | Remote Similarity | NPD6271 | Approved |
0.6012 | Remote Similarity | NPD3708 | Phase 2 |
0.6011 | Remote Similarity | NPD1895 | Discontinued |
0.6011 | Remote Similarity | NPD7709 | Discontinued |
0.6011 | Remote Similarity | NPD4744 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD2903 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD4298 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD2868 | Clinical (unspecified phase) |
0.6 | Remote Similarity | NPD4854 | Phase 3 |
0.6 | Remote Similarity | NPD2902 | Phase 2 |
0.5991 | Remote Similarity | NPD7502 | Clinical (unspecified phase) |
0.599 | Remote Similarity | NPD3905 | Phase 3 |
0.599 | Remote Similarity | NPD5885 | Approved |
0.5989 | Remote Similarity | NPD3432 | Approved |
0.5989 | Remote Similarity | NPD4213 | Clinical (unspecified phase) |
0.5988 | Remote Similarity | NPD1988 | Phase 1 |
0.5988 | Remote Similarity | NPD3405 | Phase 3 |
0.5979 | Remote Similarity | NPD7127 | Clinical (unspecified phase) |
0.5976 | Remote Similarity | NPD185 | Approved |
0.5969 | Remote Similarity | NPD7103 | Approved |
0.5968 | Remote Similarity | NPD5757 | Discontinued |
0.5965 | Remote Similarity | NPD2128 | Phase 1 |
0.5954 | Remote Similarity | NPD2150 | Discontinued |
0.595 | Remote Similarity | NPD3265 | Phase 1 |
0.5949 | Remote Similarity | NPD4924 | Clinical (unspecified phase) |
0.5949 | Remote Similarity | NPD2807 | Discontinued |
0.5949 | Remote Similarity | NPD5486 | Discontinued |
0.5943 | Remote Similarity | NPD1288 | Clinical (unspecified phase) |
0.5938 | Remote Similarity | NPD3830 | Phase 1 |
0.5936 | Remote Similarity | NPD3002 | Clinical (unspecified phase) |
0.5934 | Remote Similarity | NPD4155 | Approved |
0.5932 | Remote Similarity | NPD7988 | Suspended |
0.5928 | Remote Similarity | NPD4864 | Approved |
0.5928 | Remote Similarity | NPD4047 | Discontinued |
0.5926 | Remote Similarity | NPD1658 | Discontinued |
0.5924 | Remote Similarity | NPD8004 | Discontinued |
0.5924 | Remote Similarity | NPD1675 | Phase 1 |
0.5924 | Remote Similarity | NPD1674 | Clinical (unspecified phase) |
0.5924 | Remote Similarity | NPD1807 | Clinical (unspecified phase) |
0.592 | Remote Similarity | NPD1869 | Phase 2 |
0.592 | Remote Similarity | NPD7164 | Discontinued |
0.5916 | Remote Similarity | NPD4294 | Phase 2 |
0.5916 | Remote Similarity | NPD5464 | Approved |
0.5911 | Remote Similarity | NPD5079 | Phase 2 |
0.5909 | Remote Similarity | NPD2149 | Clinical (unspecified phase) |
0.5907 | Remote Similarity | NPD3287 | Clinical (unspecified phase) |
0.5906 | Remote Similarity | NPD2462 | Phase 3 |
0.5906 | Remote Similarity | NPD2465 | Approved |
0.5906 | Remote Similarity | NPD2466 | Phase 3 |
0.5904 | Remote Similarity | NPD2730 | Approved |
0.5904 | Remote Similarity | NPD2728 | Approved |
PubChem CID   | 25015890 |
ChEMBL   | CHEMBL476305 |
ZINC   |
Molecular Weight:   | 422.33 |
ALogP:   | 0.5008 |
MLogP:   | 3.77 |
XLogP:   | 7.902 |
# Rotatable Bonds:   | 12 |
Polar Surface Area:   | 60.61 |
# H-Bond Aceptor:   | 4 |
# H-Bond Donor:   | 1 |
# Rings:   | 4 |
# Heavy Atoms:   | 31 |